Cargando…

Insulin: a wonder drug in the critically ill?

Stress hyperglycaemia is a common event in acute critical illness. There is increasing evidence that maintaining normoglycaemia and treatment with insulin (or with glucose–insulin–potassium [GIK]), even in non-diabetic persons, is helpful in limiting organ damage after myocardial infarction, stroke,...

Descripción completa

Detalles Bibliográficos
Autores principales: Johan Groeneveld, AB, Beishuizen, Albertus, Visser, Frans C
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137286/
https://www.ncbi.nlm.nih.gov/pubmed/11983030
http://dx.doi.org/10.1186/cc1463
_version_ 1782120423019773952
author Johan Groeneveld, AB
Beishuizen, Albertus
Visser, Frans C
author_facet Johan Groeneveld, AB
Beishuizen, Albertus
Visser, Frans C
author_sort Johan Groeneveld, AB
collection PubMed
description Stress hyperglycaemia is a common event in acute critical illness. There is increasing evidence that maintaining normoglycaemia and treatment with insulin (or with glucose–insulin–potassium [GIK]), even in non-diabetic persons, is helpful in limiting organ damage after myocardial infarction, stroke, traumatic brain injury and other conditions, even though the conditions may be accompanied by insulin resistance. A landmark study now suggests that maintaining normoglycaemia with intensive insulin treatment in a heterogeneous population of critically ill patients decreases morbidity and mortality. The potential mechanisms that underlie such a beneficial effect are discussed.
format Text
id pubmed-137286
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1372862003-02-27 Insulin: a wonder drug in the critically ill? Johan Groeneveld, AB Beishuizen, Albertus Visser, Frans C Crit Care Commentary Stress hyperglycaemia is a common event in acute critical illness. There is increasing evidence that maintaining normoglycaemia and treatment with insulin (or with glucose–insulin–potassium [GIK]), even in non-diabetic persons, is helpful in limiting organ damage after myocardial infarction, stroke, traumatic brain injury and other conditions, even though the conditions may be accompanied by insulin resistance. A landmark study now suggests that maintaining normoglycaemia with intensive insulin treatment in a heterogeneous population of critically ill patients decreases morbidity and mortality. The potential mechanisms that underlie such a beneficial effect are discussed. BioMed Central 2002 2002-02-08 /pmc/articles/PMC137286/ /pubmed/11983030 http://dx.doi.org/10.1186/cc1463 Text en Copyright © 2002 BioMed Central Ltd
spellingShingle Commentary
Johan Groeneveld, AB
Beishuizen, Albertus
Visser, Frans C
Insulin: a wonder drug in the critically ill?
title Insulin: a wonder drug in the critically ill?
title_full Insulin: a wonder drug in the critically ill?
title_fullStr Insulin: a wonder drug in the critically ill?
title_full_unstemmed Insulin: a wonder drug in the critically ill?
title_short Insulin: a wonder drug in the critically ill?
title_sort insulin: a wonder drug in the critically ill?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137286/
https://www.ncbi.nlm.nih.gov/pubmed/11983030
http://dx.doi.org/10.1186/cc1463
work_keys_str_mv AT johangroeneveldab insulinawonderdruginthecriticallyill
AT beishuizenalbertus insulinawonderdruginthecriticallyill
AT visserfransc insulinawonderdruginthecriticallyill